SpeciCare

SpeciCare provides live tumor tissue banking services that enable advanced functional precision medicine approaches beyond genomics. By collecting and preserving living patient tumor samples at the time of surgery or biopsy using their proprietary Live Tissue Science™ platform, they allow extensive ex vivo drug sensitivity testing (>300 drugs), individualized vaccine creation, TIL-based immunotherapy exploration, organoid generation for research/trials access, and comprehensive genomic profiling. This approach aims to increase actionable treatment options—especially when standard-of-care fails—and improve survival rates by personalizing care based on real-time functional data from each patient’s own cancer cells. The company claims this can raise success rates from ~10% with genomics alone up to ~50% when incorporating live tissue science approaches. They are active commercially as a service provider rather than developing their own therapeutics pipeline.